Emergent BioSolutions Inc.
For the period ended Dec 31, 2025. Filed Feb 27, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Feb 27, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 9B. Other Information
During the three months ended December 31, 2025, directors and officers (as defined in Exchange Act Rule 16a-1(f)) of the Company adopted written plans for the sale of the Company’s common stock intended to satisfy the affirmative defense conditions of Exchange Act Rule 10b5-1(c) (“Rule 10b5-1 trading arrangements”) as set forth in the table below.
| Name | Position | Action | Adoption date | Rule 10b5-1 Trading Plan Provides for Purchase/Sale (1) | Total Shares of Common Stock to be Sold | Expiration Date (2) |
|---|---|---|---|---|---|---|
| Keith Katkin | Director | Adoption | November 10, 2025 | Sale | 15,481 | November 10, 2026 |
| Paul Williams | SVP, Product Business | Adoption | November 14, 2025 | Sale | 50,000 | November 14, 2026 |
| Jessica Perl | SVP, General Counsel | Adoption | November 19, 2025 | Sale | 32,801 | November 19, 2026 |
Each of the above-named directors and officers is currently and is expected to remain in compliance with his or her share ownership guidelines following the sale of any common shares pursuant to his or her Rule 10b5-1 trading arrangement.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.